Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Bharat Biotech

Merck Life Execs On APAC Firms' mRNA Tech Readiness, Start-Ups And AI

Merck Life Science’s top executives in India tell Scrip how they are helping biologics companies in APAC on their mRNA therapy journey. In the wide-ranging discussion, use of AI, the startup environment for biotechs and the changing face of manufacturing in India also came up.

Commercial Business Strategies

BioAsia 2023: Focus Research Outside US, Take ‘One Health’ Approach To Prevent Next Pandemic

Speakers from BMS, Takeda, UNICEF and more discussed how a shift in R&D focus, free flow of data on animal and human health, public sector investment and higher regulatory flexibility are key to make ‘One Health’ work and prevent future pandemics

Research & Development Vaccines

Merck KGaA Exec On Gearing For mRNA Prime Time, De-Risking Manufacturing

Benoit Opsomer, vice-president and head of bioprocessing, Asia Pacific, Merck Life Science, explains how recent targeted CDMO buyouts put the German group in pole position with services across the mRNA value chain, even as it supports global players such as BioNTech. Striking multi-country expansion of manufacturing footprint, including in China, is also underway amid rising demand for biopharma single-use assemblies.

Commercial Coronavirus COVID-19

Codagenix Eyes '23 Nasal RSV Vaccine Readout As GSK, Pfizer Set To Establish Lead

Codagenix hopes a 2023 data readout from its intranasal RSV vaccine will be an inflection point, even as GSK and Pfizer look to establish a lead in the segment. Meanwhile, a second cancer candidate has been added to Codagenix's preclinical pipeline and data for its COVID-19 vaccine and TNBC oncolytic virus are expected next year, CEO J Robert Coleman tells Scrip.

Research & Development Vaccines
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Chiron Behring Vaccines Pvt Ltd
UsernamePublicRestriction

Register